PKP2 and cardiomyopathy: Hearts treated with PSB115 (15 mg/Kg/day treated between 14 and 35 dpi) showed impaired LVEF (14% p < 0.01 vs. untreated, Figure 6A) and a trend toward increased fibrosis (Figures 6B,C) when compared to control, thus suggesting that A2A but not A2B receptors can be considered a potential target for treatment in PKP2-dependent cardiomyopathies.